Journal of Clinical Medicine (Apr 2024)

Treatment of Apathy in Parkinson’s Disease and Implications for Underlying Pathophysiology

  • Senan Maher,
  • Eoghan Donlon,
  • Gerard Mullane,
  • Richard Walsh,
  • Tim Lynch,
  • Conor Fearon

DOI
https://doi.org/10.3390/jcm13082216
Journal volume & issue
Vol. 13, no. 8
p. 2216

Abstract

Read online

Apathy is a prevalent and highly debilitating non-motor symptom of Parkinson’s disease (PD) that is often overlooked in clinical practice due to its subtle nature. This review aims to provide a comprehensive overview of the current evidence for the treatment of apathy in PD, highlighting recent advancements and emerging therapeutic avenues. In this review, we analyse a diverse array of treatment strategies for apathy in PD, including pharmacological interventions, non-pharmacological approaches, and emerging neuromodulation techniques. We evaluate the efficacy, safety, and limitations of established pharmacotherapies, such as dopaminergic agents, antidepressants, and cognitive enhancers. Additionally, we examine the promising role of non-pharmacological interventions, encompassing psychotherapies and behavioural interventions, in ameliorating apathetic symptoms. Furthermore, this review explores the effects of neuromodulation techniques on apathy, including the modulation of apathy via deep brain stimulation and emerging data on the potential influence of transcranial magnetic stimulation (TMS) on apathy in PD. Ultimately, a deeper understanding of effective treatment strategies for apathy has the potential to significantly improve the quality of life and overall well-being of individuals living with PD.

Keywords